Wells Fargo & Company Albireo Pharma, Inc. Transaction History

Wells Fargo & Company

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	BUY	$18.01 - $23.78 $378 - $499	21 Added 0.69%	3,061 $66,000
Q3 2022 Nov 14, 2022	BUY	$16.32 - $26.37 $10,248 - $16,560	628 Added 26.04%	3,040 $59,000
Q2 2022 Aug 12, 2022	SELL	$18.54 - $37.29 $28,292 - $56,904	-1,526 Reduced 38.75%	2,412 $49,000
Q1 2022 May 16, 2022	SELL	$23.94 - $33.74 $143,663 - $202,473	-6,001 Reduced 60.38%	3,938 $117,000
Q4 2021 Feb 14, 2022	BUY	$21.19 - $31.29 $135,594 - $200,224	6,399 Added 180.76%	9,939 $231,000
Q3 2021 Nov 15, 2021	BUY	$27.36 - $35.98 $88,536 - $116,431	3,236 Added 1064.47%	3,540 $110,000
Q2 2021 Aug 16, 2021	SELL	$28.9 - $36.87 $440,378 - $561,825	-15,238 Reduced 98.04%	304 $11,000
Q1 2021 May 13, 2021	SELL	$32.03 - $42.85 $830,185 - $1.11 Million	-25,919 Reduced 62.51%	15,542 $548,000
Q4 2020 Feb 09, 2021	BUY	$31.56 - $42.16 $329,107 - $439,644	10,428 Added 33.6%	41,461 $1.56 Million
Q3 2020 Nov 05, 2020	SELL	$23.19 - $41.61 $30,355 - $54,467	-1,309 Reduced 4.05%	31,033 $1.04 Million
Q2 2020 Aug 13, 2020	BUY	$14.82 - $29.92 $352,049 - $710,749	23,755 Added 276.64%	32,342 $857,000
Q1 2020 May 14, 2020	BUY	$11.67 - $27.23 $100,210 - $233,824	8,587 New	8,587 $141,000

865

Ticker ALBO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 19,612,500
Description
Albireo Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. The company offers Bylvay for the treatment of progressive familial intrahepatic cholestasis, as we...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.